Checkpoint inhibition has shown a significant impact in both target therapy and immunotherapy. Anti-PD-1 therapy was the first success in using checkpoint inhibition to conquer cancer. Over the last several years, venetoclax and CAR-T therapies have been the recent success in both targeted therapy and immunocellular therapy. Currently, magrolimab, a monoclonal antibody against CD47, is under investigation with promising preliminary data in treating relapsed/refractory hematological malignant diseases.
However, many questions are still as yet unanswered, such as mechanism, synergistic effects in combination therapy, factors impact the treatment results and long-term survival, and potential second cancer formation. We need to publish updated research on these fields.
This Research Topic aims to provide updates on checkpoint inhibition in hematologic malignancies. We welcome authors to submit Original Research, Review articles, Commentary Papers and Case Reports focusing on, but not limited to, the following subtopics:
? The mechanisms of checkpoint inhibition in hematologic malignancies
? Synergistic effects of checkpoint inhibitors in combination therapy
? The risk of secondary cancer in patients treated with immune checkpoint inhibitors
? Novel Regiment development
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
Checkpoint inhibition has shown a significant impact in both target therapy and immunotherapy. Anti-PD-1 therapy was the first success in using checkpoint inhibition to conquer cancer. Over the last several years, venetoclax and CAR-T therapies have been the recent success in both targeted therapy and immunocellular therapy. Currently, magrolimab, a monoclonal antibody against CD47, is under investigation with promising preliminary data in treating relapsed/refractory hematological malignant diseases.
However, many questions are still as yet unanswered, such as mechanism, synergistic effects in combination therapy, factors impact the treatment results and long-term survival, and potential second cancer formation. We need to publish updated research on these fields.
This Research Topic aims to provide updates on checkpoint inhibition in hematologic malignancies. We welcome authors to submit Original Research, Review articles, Commentary Papers and Case Reports focusing on, but not limited to, the following subtopics:
? The mechanisms of checkpoint inhibition in hematologic malignancies
? Synergistic effects of checkpoint inhibitors in combination therapy
? The risk of secondary cancer in patients treated with immune checkpoint inhibitors
? Novel Regiment development
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
